Baidu
map

心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Heart：PCI在老年ACS患者中应用减少但疗效好

2014-06-04 高晓方 译 医学论坛网

PCI老年ACS患者
关注

意大利一项研究表明，在老年急性冠脉综合征(ACS)患者中，经皮冠脉介入(PCI)应用随背景风险升高而减少;但对这类人群应用PCI治疗与其远期生存获益具有相关性。论文于5月26日在线发表于《心脏》(Heart)。 此项观察性队列研究共纳入698例75岁以上的ACS患者(女性358例，平均年龄83岁)，并利用经验证的死亡预测工具Silver Code(SC)对受试者的背景风险进行分层。计算PCI应用

意大利一项研究表明，在老年急性冠脉综合征(ACS)患者中，经皮冠脉介入(PCI)应用随背景风险升高而减少;但对这类人群应用PCI治疗与其远期生存获益具有相关性。论文于5月26日在线发表于《心脏》(Heart)。

此项观察性队列研究共纳入698例75岁以上的ACS患者(女性358例，平均年龄83岁)，并利用经验证的死亡预测工具Silver Code(SC)对受试者的背景风险进行分层。计算PCI应用的多变量比值比(OR)，以及依据PCI应用的1年死亡危险比(HR)。

结果显示，纳入患者中176例伴有ST段抬高型心肌梗死(STEMI)。对阳性和阴性预测因素进行校正之后，SC评分每升高1，PCI应用机率降低11%，1年死亡风险则升高10%。PCI可随SC升高而更大程度的降低1年死亡率;SC为0～3、4～6、7～10和≥11时，HR分别为0.8、0.41、0.41和0.26。

原始出处：


Di Bari M1, Balzi D2, Fracchia S1, Barchielli A2, Orso F1, Sori A3, Spini S4, Carrabba N5, Santoro GM6, Gensini GF7, Marchionni N1; For the Acute Myocardial Infarction in Florence 2 (AMI Florence-2) Working Group.Decreased usage and increased effectiveness of percutaneous coronary intervention in complex older patients with acute coronary syndromes.Heart. 2014 May 26. pii: heartjnl-2013-305445. doi: 10.1136/heartjnl-2013-305445. [Epub ahead of print]


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1279055, encodeId=d8e512e90553e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355864, encodeId=21b1135586495, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562239, encodeId=092d1562239fd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574965, encodeId=f57415e496511, content=<a href='/topic/show?id=52ab188e48' target=_blank style='color:#2F92EE;'>#ACS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1887, encryptionId=52ab188e48, topicName=ACS患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9f16042984, createdName=neurosurgeon, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
    2014-06-06 yaanren

    #ACS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1279055, encodeId=d8e512e90553e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355864, encodeId=21b1135586495, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562239, encodeId=092d1562239fd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574965, encodeId=f57415e496511, content=<a href='/topic/show?id=52ab188e48' target=_blank style='color:#2F92EE;'>#ACS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1887, encryptionId=52ab188e48, topicName=ACS患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9f16042984, createdName=neurosurgeon, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
    2014-06-06 zhaojie88

    #ART#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1279055, encodeId=d8e512e90553e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355864, encodeId=21b1135586495, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562239, encodeId=092d1562239fd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574965, encodeId=f57415e496511, content=<a href='/topic/show?id=52ab188e48' target=_blank style='color:#2F92EE;'>#ACS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1887, encryptionId=52ab188e48, topicName=ACS患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9f16042984, createdName=neurosurgeon, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
    2014-06-06 爆笑小医

    #HEART#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1279055, encodeId=d8e512e90553e, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355864, encodeId=21b1135586495, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562239, encodeId=092d1562239fd, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574965, encodeId=f57415e496511, content=<a href='/topic/show?id=52ab188e48' target=_blank style='color:#2F92EE;'>#ACS患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1887, encryptionId=52ab188e48, topicName=ACS患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf9f16042984, createdName=neurosurgeon, createdTime=Fri Jun 06 04:16:00 CST 2014, time=2014-06-06, status=1, ipAttribution=)]
    2014-06-06 neurosurgeon

    #ACS患者#

    0

相关资讯

OCC 2014：当PCI遭遇消化道大出血

经皮冠状动脉介入(PCI)术后患者发生消化道大出血无疑是心内科医生临床工作中遇到的比较头痛的问题，一边是支架内血栓形成的风险，一边是消化道出血造成的危害，如何权衡利弊?让复旦大学附属中山医院葛雷教授来给你支招吧~​ 四大原则请牢记​ 接受PCI治疗的冠心病患者无论在围手术期还是术后长期，血栓形成风险均明显增高。血小板激活是PCI术后相关血栓形成过程中最关键的因素之一，因此，包括阿司匹林和氯吡格

IVUS指导下直接PCI救治高危急性心肌梗死一例

患者，男性，48岁。因突发胸痛3小时来诊。查体：血压120/70mmHg，神志清楚，双肺呼吸音清，无罗音，心率76次/分，律齐，无杂音，双下肢无水肿。急诊心电图示V1-V4导联ST段弓背向上型抬高。诊断为：急性前壁心肌梗死，符合直接PCI手术指征，积极准备后行急诊冠状动脉造影术。造影显示（图1A-C）：LM无狭窄，LAD开口起完全闭塞，LCX、OM、RCA存在不同程度动脉粥样硬化性狭窄，血流TIM

Circ Cardiovasc Interv：冠心病患者PCI后比伐卢定抗凝治疗 真实世界研究证据（EVENT和EUROVISION注册研究）

EVENT注册研究的一项分析显示，行PCI的稳定型缺血性心脏病（IHD）或非ST抬高型急性冠脉综合征（NSTE-ACS）患者使用比伐卢定与肝素相比可减少一半的出血风险。在2014年ACC年会上刚刚发布了HEAT-PPCI试验结果，EVENT注册研究的发表无疑又把我们带回了一个老问题，抗凝用新药还是老药更好？哪些患者适合新药/老药？Sripal Bangalore博士（纽约大学医学院）指出，对于IH

JAMA：SYNTAX积分在CABG与PCI在血运重建方面比较

近年来，随着人民生活水平的不断提高，我国冠心病的发病率和死亡率也逐年升高，并呈现患者年轻化趋势。目前的主要治疗手段包括生活方式干预、药物治疗、器 械治疗即血管成形术[1]。在血管成形术中，包括经皮冠状动脉介入术（PCI）和冠状动脉旁路移植术（CABG）两种主要手段[2]。在部分冠脉病变的血 管成形术术式的选择上，PCI与CABG的选择问题一直存在争论。随着药物支架的广泛应用，PCI的治疗范

OCC 2014：陈纪言教授介绍CTO介入治疗现状与挑战

5月30日上海国际会议中心世纪厅，来自广东省人民医院的陈纪言教授做了题为“CTO介入治疗现状与挑战”的汇报讲座。 陈纪言教授介绍了目前慢性完全闭塞冠状动脉病变(CTO)治疗的现状，他指出，CTO是一个比较困难的介入治疗疾病，该疾病比较常见，约占总体PCI的10%~15%，但是它是介入治疗中最后一个没有攻克的堡垒，介入成功率仅有50%~80%。但是通过近十年的努力，CTO的治疗有了很大的突破。导丝

OCC 2014：韩雅玲院士强调要重视知识普及 缩短实践与指南差距

5月30日上午，沈阳军区总院的韩雅玲院士在其“我国冠心病介入治疗现状及国产器械进展”的汇报中指出，近年来，全国范围内冠心病发病率逐年上升，冠心病治疗方式也在逐渐更新，介入治疗有显著增加。但是值得注意的是，冠心病总死亡率基本持平，并没有很大幅度的降低。这需要我们进行更多的研究以确定适宜的治疗指征，并不断革新介入治疗方式和器械。韩院士重点介绍了多种新型支架，包括DES、无载体DES及生物全降解支架。药

Baidu
map
Baidu
map
Baidu
map